Shareholders are not impatient, as you seem to be. The company is on track, and the release of clinical trial results imminent. With three separate drug development programs all in clinical trials, the odds of success of at least one are high, and any such success would drive share price very significantly higher.
Patience. P a t i e n c e......... something we shareholders have.
News 
Market Data 
Discover 
